Form 8-K - Current report:
SEC Accession No. 0001193125-26-059334
Filing Date
2026-02-19
Accepted
2026-02-19 16:03:06
Documents
12
Period of Report
2026-02-19
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.02: Results of Operations and Financial Condition
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K cadl-20260219.htm   iXBRL 8-K 57823
2 EX-99.1 cadl-ex99_1.htm EX-99.1 17825
3 GRAPHIC img160460863_0.jpg GRAPHIC 21223
  Complete submission text file 0001193125-26-059334.txt   226376

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT cadl-20260219.xsd EX-101.SCH 26968
14 EXTRACTED XBRL INSTANCE DOCUMENT cadl-20260219_htm.xml XML 5112
Mailing Address 117 KENDRICK STREET SUITE 450 NEEDHAM MA 02494
Business Address 117 KENDRICK STREET SUITE 450 NEEDHAM MA 02494 617-916-5445
Candel Therapeutics, Inc. (Filer) CIK: 0001841387 (see all company filings)

EIN.: 522214851 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40629 | Film No.: 26654237
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)